Introduction
Ascites is the most common complication of cirrhosis, is seen in approximately 90% of individuals with end-stage liver disease (ESLD). 1 It results in frequent, repeated hospitalisations due to symptoms such as pain and breathlessness. Unresponsiveness to, or intolerance of, diuretics (refractory ascites (RA)) is a poor prognostic sign in ESLD; without liver transplantation (LT), median life expectancy is 6 months. 2, 3 We and others have shown that less than 10% of patients with advanced cirrhosis are eligible for LT due to comorbidity, alcohol recidivism, substance misuse and psychosocial issues. 1, 4 Thus, in many with RA and ESLD, the management remains palliative.
The commonest palliative intervention for RA is frequent large-volume paracentesis (LVP), on average every 10-14 days. 2 To ensure amenability for drainage, patients wait until their ascites is tense, with consequent increased symptom severity. 5 RA is therefore an important determinant of reduced quality of life (QoL) in ESLD. 6 Individuals with RA often have contraindications to other interventions such as transjugular intrahepatic portosystemic shunts (TIPSS) and the ALFA pump. [7] [8] [9] Additionally, these are invasive techniques, thus making them less suitable as palliative interventions.
Long-term abdominal drains (LTAD) are small-bore flexible drains tunnelled subcutaneously on the abdominal wall, under local anaesthetic, with ultrasound guidance. 10 Community nurses or, if willing, patients/carers drain the ascites at home dependent on symptoms (e.g. 1-2 L, two to three times per week). LTAD are an accepted palliative strategy in malignant ascites, though to date have not been researched in ESLD.
In the United Kingdom, deaths from chronic liver disease have increased 400% since 1970, in sharp contrast to other chronic conditions. 11 In 2009, over 70% with ESLD died in hospital. 12 There are national calls to improve the overall end-of-life care (EoLC) in ESLD. 13 Here, we report our early experience with palliative LTAD in individuals with RA due to ESLD.
Methods
A retrospective, single centre, case review was performed of patients who underwent LTAD placement for RA secondary to ESLD at Brighton and Sussex University Hospital NHS Trust (BSUH) between August 2011 and March 2013.
These patients were not LT candidates due to either comorbidity, alcohol recidivism, substance misuse and or psychosocial factors; often in combination. Suitability for LTAD was assessed by a multidisciplinary group including hepatologists and palliative medicine physicians. Prior spontaneous bacterial peritonitis (SBP) did not automatically preclude LTAD insertion. LTAD was discussed with patients and family (if present) and all patients gave written consent prior to insertion.
Two LTADs were available in England at the time: PleurX ® (UK Medical Ltd, Basingstoke, UK) and Rocket Medical (Watford, UK). Rocket Medical LTAD were utilised due to experience among clinicians siting the LTAD and community nursing teams providing ongoing support.
LTADs were inserted under ultrasound guidance by J.M. and M.A. as per manufacturer's instructions. 10 Local hospital policy regarding use of blood/clotting products was followed (platelet count <50 × 10 9 and or international normalised ratio (INR) > 2); however, none were required. Data were collected retrospectively from patient records. Following review of preliminary data from the first five cases, prophylactic norfloxacin/ciprofloxacin use post-LTAD insertion was initiated.
As of April 2016, all but one patient are deceased, hence obtaining consent for publication from next of kin was considered inappropriate; the surviving patient gave written consent.
Results
During the study period, eight patients were deemed appropriate for LTAD; seven underwent successful insertion, one dying soon after assessment. All patients had clinical, biochemical and radiological evidence of cirrhosis and LT was contraindicated due to either comorbidity or alcohol recidivism (Table 1) . Other comorbidities included chronic obstructive pulmonary disease, hypertension, stroke, congestive cardiac failure, peripheral vascular disease, atrial fibrillation and previous bowel cancer.
This was an elderly, predominantly female, cohort, median age at LTAD insertion 71 years (55-80); nonalcoholic fatty liver disease (NAFLD) being the dominant aetiology of ESLD (57%) ( Table 1) . Five (71%) had Child Pugh B and two Child Pugh C disease (29%). No patient had a prior history of SBP. All patients had at least one comorbidity, the commonest being diabetes mellitus (DM) (71%).
Of the seven cases, one remained on diuretics at the time of LTAD insertion. In the remaining six, diuretics had been stopped historically due to intolerance (hyponatraemia and or renal dysfunction).
In the 6 months prior to LTAD insertion, the median number of LVP episodes was 7 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Following the intervention, Hepatology-related related hospital attendance reduced from a median of 9 (4-21) to 1 (0-4); however, none of these attendances were for management of ascites or LVP (Table 1) .
Complications
Subsequent to LTAD insertion, one patient developed drain site cellulitis, treated successfully with antibiotics. A second developed cellulitis requiring LTAD removal (drain duration 219 days); however, LTAD was reinstated at patient's request once cellulitis had resolved (see below); a third developed hepatic encephalopathy (HE), the cause of which is unclear. Ascitic fluid culture obtained from the LTAD grew Pseudomonas aeruginosa and Corynebacterium striatum, therefore must be interpreted with caution. There was no improvement with empirical antibiotic treatment, the patient subsequently developed GI bleeding and was managed palliatively with fast-track home for EoLC. Median survival following LTAD insertion was 29 days . Six patients died during follow up, mortality being liver related in all. The place of death in four cases was recorded as in hospital, one in their own home and one in a care home. The single surviving patient had a second LTAD sited, at their request, after removal of the first due to cellulitis (see above). The second LTAD remains in situ (436 days at last follow up).
Discussion
This is a single-centre experience of palliative Rocket Medical LTAD in RA due to ESLD. Despite the small sample size, our data suggest that, when used as part of a multidisciplinary approach, LTAD may be a safe and effective palliative intervention in this cohort. Technical success was 100% with no further LVP requirement. Median survival following LTAD insertion was 29 days; however, patients were referred late in their disease trajectory having already undergone multiple LVPs, resulting in less scope for intervention earlier on a palliative pathway. Complications observed with LTAD were not life threatening and in none did the LTAD conclusively and directly contribute to death; this being liver related in all.
Patients with ESLD have complex and challenging medical needs related to a fluctuating disease trajectory (severe near fatal exacerbations or decompensations), ongoing alcohol use, mental health issues and social isolation/stigmatisation. Additional factors include younger age (90% of patients are <70 years and 1:10 are <40 years), hence may not have engaged with health services. 12 Finally, there is a consistent lack of public, as well as healthcare professional, awareness that ESLD is a lifelimiting condition. 12 LTAD are an accepted palliative strategy in malignant ascites. A NICE (National Institute for Health and Care Excellence) technology appraisal (review of nine studies, 180 patients, all using PleurX ® drains) lends credence to LTAD use within this setting with low complication rates (device related infections 5.8%), 100% technical success and improved symptom control. 14 Traditionally, use of LTAD in ESLD has been hampered by concerns regarding infection, acceptability and tolerability. This is despite the potential advantages (avoidance of frequent hospitalisations and some LVP-associated complications, spending the majority of remaining life at home, improved QoL and possible economic benefits).
There is thus limited published data on LTAD in an ESLD cohort with only small case series (total 66 patients) [15] [16] [17] [18] , all using PleurX ® drains. Catheter-related infections were low (7/66, all being bacterial peritonitis) with LTAD remaining in situ for up to 4 months. However, prophylactic antibiotics were only used in one study. 15 In another case series of 46 patients (nine with portal hypertension), Semadeni et al. 19 reported 98% technical success rate, 9% bacterial peritonitis, with a mean catheter (PleurX ® ) and patient survival of 65 and 91 days, respectively; the best survival was seen in those with portal hypertension (111 and 192 days, respectively).
Since this was an EoL cohort, our main emphasis was on improving QoL. The reasons why we did not conclusively observe SBP post-LTAD insertion are unclear but could include the small sample size and short follow up. Additionally, earlier studies in malignant ascites have shown that risk of peritonitis is significantly lower with tunnelled versus non-tunnelled drains (4.4% vs 34.2%). 20 Nonetheless, we are cognisant of the potential for SBP in ESLD and hence introduced antibiotic prophylaxis after the first five patients.
Encouraged by this and our own data, our group has obtained National Institute for Health Research (NIHR) funding for a prospective feasibility randomised controlled trial comparing palliative Rocket LTAD versus LVP in ESLD (REDUCe Study, ISRCTN 30697116). Embedded are assessments of whether an ESLD cohort can be managed outside of secondary care, a concurrent qualitative study, QoL and health economic assessments.
In conclusion, we provide preliminary evidence of the safety and effectiveness of palliative Rocket LTAD in the management of patients with RA due to ESLD. EoLC in ESLD remains an unmet need and will mandate a paradigm shift in attitudes and practice both among healthcare professionals and wider society.
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